| 1 | A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma | 4.8 | 72 | Citations (PDF) |
| 2 | Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response | 5.8 | 119 | Citations (PDF) |
| 3 | Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma | 4.8 | 404 | Citations (PDF) |
| 4 | A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response | 4.8 | 765 | Citations (PDF) |
| 5 | Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans | 4.8 | 46 | Citations (PDF) |
| 6 | PD-1 identifies the patient-specific CD8<sup>+</sup> tumor-reactive repertoire infiltrating human tumors | 7.1 | 1,045 | Citations (PDF) |
| 7 | Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions | 4.8 | 402 | Citations (PDF) |
| 8 | Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy | 1.8 | 1,051 | Citations (PDF) |
| 9 | Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantationBlood, 2013, 122, 4129-4139 | 5.8 | 528 | Citations (PDF) |
| 10 | Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma Free | 4.8 | 93 | Citations (PDF) |
| 11 | TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients | 3.5 | 162 | Citations (PDF) |
| 12 | Audiovestibular Dysfunction Associated with Adoptive Cell Immunotherapy for Melanoma | 1.6 | 33 | Citations (PDF) |
| 13 | Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes | 1.8 | 99 | Citations (PDF) |
| 14 | Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment | 1.8 | 271 | Citations (PDF) |
| 15 | Evaluation of γ-Retroviral Vectors That Mediate the Inducible Expression of IL-12 for Clinical Application | 1.8 | 31 | Citations (PDF) |
| 16 | Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer FreeBlood, 2012, 119, 5688-5696 | 5.8 | 187 | Citations (PDF) |
| 17 | The Stoichiometric Production of IL-2 and IFN-γ mRNA Defines Memory T Cells That Can Self-Renew After Adoptive Transfer in Humans | 8.9 | 52 | Citations (PDF) |
| 18 | Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma | 1.5 | 11 | Citations (PDF) |
| 19 | IRF5 gene polymorphisms in melanoma | 5.1 | 40 | Citations (PDF) |
| 20 | B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells FreeBlood, 2012, 119, 2709-2720 | 5.8 | 1,494 | Citations (PDF) |
| 21 | Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor | 5.1 | 209 | Citations (PDF) |
| 22 | New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer | 5.1 | 47 | Citations (PDF) |
| 23 | Adoptive immunotherapy for cancer: harnessing the T cell response | 32.7 | 1,574 | Citations (PDF) |
| 24 | Augmented Lymphocyte Expansion from Solid Tumors With Engineered Cells for Costimulatory Enhancement | 1.8 | 20 | Citations (PDF) |
| 25 | Adoptive Cell Therapy for Patients with Melanoma | 1.8 | 27 | Citations (PDF) |
| 26 | Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression | 4.8 | 457 | Citations (PDF) |
| 27 | Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy | 4.8 | 2,065 | Citations (PDF) |
| 28 | T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis | 6.2 | 955 | Citations (PDF) |
| 29 | Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL | 1.8 | 126 | Citations (PDF) |
| 30 | Enrichment of CD8+ Cells From Melanoma Tumor-infiltrating Lymphocyte Cultures Reveals Tumor Reactivity for Use in Adoptive Cell Therapy | 1.8 | 90 | Citations (PDF) |
| 31 | A Simplified Method for the Clinical-scale Generation of Central Memory-like CD8+ T Cells After Transduction With Lentiviral Vectors Encoding Antitumor Antigen T-cell Receptors | 1.8 | 67 | Citations (PDF) |
| 32 | Adoptive Cell Therapy | 1.1 | 91 | Citations (PDF) |
| 33 | Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19Blood, 2010, 116, 4099-4102 | 5.8 | 1,184 | Citations (PDF) |
| 34 | Thoracic metastasectomy for adoptive immunotherapy of melanoma: A single-institution experience | 2.2 | 19 | Citations (PDF) |
| 35 | Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy | 4.8 | 179 | Citations (PDF) |
| 36 | CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma | 4.8 | 400 | Citations (PDF) |
| 37 | Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2 | 6.2 | 2,573 | Citations (PDF) |
| 38 | Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy | 1.0 | 47 | Citations (PDF) |
| 39 | Adoptive cell therapy for the treatment of patients with metastatic melanoma | 3.7 | 583 | Citations (PDF) |
| 40 | Ocular and Systemic Autoimmunity after Successful Tumor-Infiltrating Lymphocyte Immunotherapy for Recurrent, Metastatic Melanoma | 6.2 | 87 | Citations (PDF) |
| 41 | Impact of a Recombinant Fowlpox Vaccine on the Efficacy of Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes in a Patient With Metastatic Melanoma | 1.8 | 16 | Citations (PDF) |
| 42 | Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired FreeBlood, 2009, 114, 1537-1544 | 5.8 | 1,567 | Citations (PDF) |
| 43 | Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. | 5.8 | 1,250 | Citations (PDF) |
| 44 | Liver Resection for Metastatic Melanoma with Postoperative Tumor-Infiltrating Lymphocyte Therapy | 1.8 | 30 | Citations (PDF) |
| 45 | Adoptive cell transfer: a clinical path to effective cancer immunotherapy | 36.0 | 1,589 | Citations (PDF) |
| 46 | Adoptive Cell Therapy for Patients with Melanoma, Using Tumor-Infiltrating Lymphocytes Genetically Engineered to Secrete Interleukin-2 | 2.4 | 151 | Citations (PDF) |
| 47 | Cancer Immunotherapy | 25.2 | 40 | Citations (PDF) |
| 48 | Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens | 17.2 | 1,197 | Citations (PDF) |
| 49 | Relationship of p53 Overexpression on Cancers and Recognition by Anti-p53 T Cell Receptor-Transduced T Cells | 2.4 | 40 | Citations (PDF) |
| 50 | Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy | 1.8 | 274 | Citations (PDF) |
| 51 | A T cell receptor associated with naturally occurring human tumor immunity | 5.4 | 36 | Citations (PDF) |
| 52 | Adoptive Cell Transfer Therapy | 3.0 | 93 | Citations (PDF) |
| 53 | Survival, Persistence, and Progressive Differentiation of Adoptively Transferred Tumor-Reactive T Cells Associated with Tumor Regression | 1.8 | 257 | Citations (PDF) |
| 54 | Persistence of Multiple Tumor-Specific T-Cell Clones Is Associated with Complete Tumor Regression in a Melanoma Patient Receiving Adoptive Cell Transfer Therapy | 1.8 | 292 | Citations (PDF) |
| 55 | Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapyBlood, 2005, 105, 241-250 | 5.8 | 279 | Citations (PDF) |
| 56 | Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma | 17.2 | 1,627 | Citations (PDF) |
| 57 | Transfer of a TCR Gene Derived from a Patient with a Marked Antitumor Response Conveys Highly Active T-Cell Effector Functions | 2.4 | 284 | Citations (PDF) |
| 58 | Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes | 5.4 | 310 | Citations (PDF) |
| 59 | Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100209-217 and gp100209-217T210M | 3.4 | 12 | Citations (PDF) |
| 60 | Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells | 3.3 | 17 | Citations (PDF) |
| 61 | Adoptive-cell-transfer therapy for the treatment of patients with cancer | 36.0 | 589 | Citations (PDF) |
| 62 | Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients | 1.8 | 792 | Citations (PDF) |
| 63 | Cell Transfer Therapy for Cancer: Lessons from Sequential Treatments of a Patient With Metastatic Melanoma | 1.8 | 53 | Citations (PDF) |
| 64 | Functional Heterogeneity of Vaccine-Induced CD8+ T Cells1 | 0.8 | 83 | Citations (PDF) |
| 65 | A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma | 1.8 | 374 | Citations (PDF) |
| 66 | TCR stimulation protects CD8 T cells from CD95 mediated apoptosis | 0.5 | 11 | Citations (PDF) |
| 67 | Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma | 1.8 | 340 | Citations (PDF) |
| 68 | Expansion and Characterization of T Cells Transduced with a Chimeric Receptor against Ovarian Cancer | 2.4 | 49 | Citations (PDF) |
| 69 | Antitumor Immunization with a Minimal Peptide Epitope (G9–209–2M) Leads to a Functionally Heterogeneous CTL Response | 1.8 | 48 | Citations (PDF) |
| 70 | Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma | 27.2 | 1,592 | Citations (PDF) |
| 71 | Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. | 6.2 | 61 | Citations (PDF) |
| 72 | Frequency and histological appearance of adenomas in multiple intestinal neoplasia mice are unaffected by severe combined immunodeficiency (scid) mutation | 2.9 | 13 | Citations (PDF) |
| 73 | MHC Class I-Mediated Antigen Presentation and Induction of CD8+ Cytotoxic T-Cell Responses in Autoimmune Diabetes-Prone NOD Mice | 3.5 | 23 | Citations (PDF) |
| 74 | Gene Mapping in a Murine Cell Line by Immunoselection with Cytotoxic T Lymphocytes | 2.0 | 10 | Citations (PDF) |
